{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:50:18Z","timestamp":1782143418489,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s41030-026-00357-y","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:55:44Z","timestamp":1775667344000},"page":"425-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical Considerations for Managing Transitions from Parenteral Prostacyclins to Oral Selexipag in Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-1707","authenticated-orcid":false,"given":"Jean M.","family":"Elwing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4057-0540","authenticated-orcid":false,"given":"Christina","family":"Benninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4267-1918","authenticated-orcid":false,"given":"Paul","family":"Strachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4494-7497","authenticated-orcid":false,"given":"Korawin","family":"Triyasakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla","family":"Choren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9661-0231","authenticated-orcid":false,"given":"B. Kody","family":"Timms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-6010","authenticated-orcid":false,"given":"Lori","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"1","key":"357_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019894534","volume":"10","author":"J Dubroff","year":"2020","unstructured":"Dubroff J, Melendres L, Lin Y, Beene DR, Ketai L. High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude. Pulm Circ. 2020;10(1):2045894019894534.","journal-title":"Pulm Circ"},{"issue":"3","key":"357_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2023.104168","volume":"52","author":"A Boucly","year":"2023","unstructured":"Boucly A, Gerges C, Savale L, et al. Pulmonary arterial hypertension. Presse Med. 2023;52(3):104168.","journal-title":"Presse Med"},{"issue":"6","key":"357_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/17476348.2017.1317599","volume":"11","author":"R Del Pozo","year":"2017","unstructured":"Del Pozo R, Hernandez Gonzalez I, Escribano-Subias P. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med. 2017;11(6):491\u2013503.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"357_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.70059","volume":"15","author":"IM Robbins","year":"2025","unstructured":"Robbins IM, Hemnes AR. How a most unlikely drug changed the outcome of pulmonary arterial hypertension. Pulm Circ. 2025;15(1):e70059.","journal-title":"Pulm Circ"},{"issue":"38","key":"357_CR5","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"key":"357_CR6","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fmed.2025.1643220","volume":"12","author":"KM Saleh","year":"2025","unstructured":"Saleh KM, Mallat J, Mohammed S, et al. Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis. Front Med. 2025;12:2025.","journal-title":"Front Med"},{"issue":"4","key":"357_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/20458940211046761","volume":"11","author":"K Morland","year":"2021","unstructured":"Morland K, Raina A, Nails A, Classi P, Etschmaier M, Frantz RP. Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension. Pulm Circ. 2021;11(4):20458940211046761.","journal-title":"Pulm Circ"},{"key":"357_CR8","doi-asserted-by":"publisher","first-page":"175346662412898","DOI":"10.1177\/17534666241289807","volume":"18","author":"A Aguirre-Camacho","year":"2024","unstructured":"Aguirre-Camacho A. Patients\u2019 perspectives on the challenges associated with receiving non-oral pulmonary arterial hypertension treatment: a mixed methods study. Ther Adv Respir Dis. 2024;18:17534666241289808.","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"357_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/jcm8040481","volume":"8","author":"C Picken","year":"2019","unstructured":"Picken C, Fragkos KC, Eddama M, Coghlan G, Clapp LH. Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and meta-analysis. J Clin Med. 2019;8(4):481.","journal-title":"J Clin Med"},{"issue":"8","key":"357_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.healun.2010.03.008","volume":"29","author":"MS Kingman","year":"2010","unstructured":"Kingman MS, Tankersley MA, Lombardi S, Spence S, Torres F, Chin KS. Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. J Heart Lung Transplant. 2010;29(8):841\u20136.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"357_CR11","doi-asserted-by":"publisher","first-page":"2401325","DOI":"10.1183\/13993003.01325-2024","volume":"64","author":"KM Chin","year":"2024","unstructured":"Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325.","journal-title":"Eur Respir J"},{"issue":"1","key":"357_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12325-025-03401-6","volume":"43","author":"M Clarke","year":"2026","unstructured":"Clarke M, Ataya A, Turkin AM, et al. Transitioning between treprostinil formulations: evidence and strategies. Adv Ther. 2026;43(1):20\u201348.","journal-title":"Adv Ther"},{"key":"357_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pupt.2016.07.007","volume":"40","author":"A Ataya","year":"2016","unstructured":"Ataya A, Somoracki A, Cope J, Alnuaimat H. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2016;40:39\u201343.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"357_CR14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1086\/688711","volume":"6","author":"R Oudiz","year":"2016","unstructured":"Oudiz R, Agarwal M, Rischard F, De Marco T. An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension. Pulm Circ. 2016;6(4):532\u20138.","journal-title":"Pulm Circ"},{"issue":"2","key":"357_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4103\/2045-8932.114768","volume":"3","author":"RN Channick","year":"2013","unstructured":"Channick RN, Frantz RP, Kawut SM, et al. A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost. Pulm Circ. 2013;3(2):381\u20138.","journal-title":"Pulm Circ"},{"key":"357_CR16","unstructured":"UPTRAVI\u00ae (selexipag) tablets, for oral use. Prescribing Information, July 2022. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/UPTRAVI-pi.pdf. Accessed Sept 1, 2025."},{"issue":"26","key":"357_CR17","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333.","journal-title":"N Engl J Med"},{"key":"357_CR18","doi-asserted-by":"publisher","unstructured":"Elwing JM, Krishnan M, Parikh KS, et al. Transitioning prostacyclin pathway agents to oral selexipag in patients with pulmonary arterial hypertension: a systematic literature review. Adv Ther. 2026. https:\/\/doi.org\/10.1007\/s12325-026-03491-w.","DOI":"10.1007\/s12325-026-03491-w"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00357-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00357-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00357-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:24:31Z","timestamp":1782141871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00357-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["357"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00357-y","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jean M. Elwing has served as a consultant for United Therapeutics, Aerovate, Gossamer Bio, Liquidia, Merck, Johnson & Johnson, Insmed, and Pulmovant. She has also participated in clinical research studies funded by United Therapeutics, Gossamer Bio, Bayer, Acceleron\/Merck, Altavant, Aerovate, Pharmosa\/Liquidia, Johnson & Johnson, Lung LLC, and Pulmovant. Christina Benninger, Paul Strachan, and B. Kody Timms were employees and shareholders of Johnson & Johnson at the time the commentary was developed. Korawin Triyasakom and Marla Choren are employees and shareholders of Johnson & Johnson. Lori Reed has served as a consultant for Johnson & Johnson and United Therapeutics. She has also participated in a speakers\u2019 bureau for Johnson & Johnson, Liquidia, Merck, and United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}